<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606112</url>
  </required_header>
  <id_info>
    <org_study_id>MSI-1436C-103</org_study_id>
    <nct_id>NCT00606112</nct_id>
  </id_info>
  <brief_title>A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers</brief_title>
  <official_title>A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genaera Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genaera Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerance of a single intravenous
      (through a vein) dose of trodusquemine (MSI-1436) in obese, type 2 diabetics.

      Different amounts of trodusquemine (MSI-1436) will be given to each volunteer group
      throughout the study.

      Another purpose is to evaluate the pharmacokinetics (PK - the study of the way the drug
      enters and leaves the blood and tissues over time) of trodusquemine (MSI-1436).

      Finally, this study will also determine whether trodusquemine (MSI-1436) has any effect on
      appetite, mood or behavior, and selective biomarkers (substances in your blood that may
      change in response to the study drug).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerance of a single intravenous dose of trodusquemine (MSI-1436) in obese, type 2 diabetics</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trodusquemine (MSI-1436)</intervention_name>
    <description>A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female obese or overweight type 2 diabetic subjects, between 18 and 55 years
             old (inclusive)

          2. either treatment naive or who are inadequately controlled on either metformin alone or
             metformin in combination with a sulfonylurea. Subjects on metformin in combination
             with a sulfonylurea will be allowed a 2 week period to wash out the sulfonylurea
             before dosing.

          3. have a fasting blood sugar of ≥ 100 mg/dL, hemoglobin A1C ≥ 7.5% (but ≤ 11.0%).
             Subjects on a combination of metformin and sulfonylurea must have a hemoglobin A1C ≥
             7.5% (but ≤ 10.0%);

          4. non-smoker

          5. body mass index (BMI) of 27-40 kg/m2

        Exclusion Criteria:

          1. likely allergy or sensitivity to any components of Trodusquemine (MSI-1436) for
             Injection based on known allergies to drugs of the same class;

          2. any subject with a history of allergy (rash, hives, breathing difficulty, etc.) to any
             medications, either prescription or nonprescription, including dietary supplements or
             herbal medications;

          3. any subject with a history of severe allergy or bronchial asthma;

          4. a clinically significant history of or current abnormality or disease of any organ
             system, including renal, hepatic, gastrointestinal, cardiovascular (except
             hyperlipidemia or controlled hypertension), pulmonary (including chronic asthma),
             endocrine (except diabetes), central nervous, or hematologic systems, or recent
             clinically significant surgery;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kipnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>dgd Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilbert R. Weiner, D.O. AOBFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>dgd Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2008</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Gast, MD, PhD</name_title>
    <organization>Genaera Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

